kymera therapeutics announces dosing of first participant in phase 1 clinical trial of kt-621, a first-in-class oral stat6 degrader, for the treatment of th2 immuno-inflammatory diseases
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple...